Track Record

Transactions

The team has completed over 300 transactions and engagements for its clients — valued at over $35 billion — as Bookrunner, Co-Manager, Lead Placement Agent, Co-Placement Agent or Advisor.

Featured Transactions

April 2025Alcyone TherapeuticsBrookline served as Exclusive Placement Agent for the Series F Convertible Preferred stock offering.
September 2025Sale to BiogenBiogen acquired Alcyone Therapeutics in 2025. Brookline served as Alcyone's financial advisor.
July 2026Neela TherapeuticsNeela Therapeutics was spun out of the acquisition and Brookline served as the Exclusive Placement Agent for a Convertible Note in 2026.

Selected Client Transactions

NightHawk Biosciences
$13,800,000
Follow-OnFinancial Advisor
November 2018
RiverNorth Opportunistic Municipal Income Fund
$127,000,000
IPOCo-Manager
October 2018
Verastem Oncology
$150,000,000
Registered Direct New Issue Convertible DebtImmediately Redeemable
October 2018
Q BioMed
$4,000,000
PIPEFinancial Advisor
September 2018
Veru
$10,000,000
Follow-OnCo-Manager
September 2018
Titan Pharmaceuticals
$10,900,000
Follow-OnCo-Manager
September 2018
Cardax
$1,440,000
Warrant ExchangeSole Solicitation Agent
August 2018
Neumentum
$7,600,000
Series A-1 Convertible Preffered StockSole Placement Agent
August 2018
Progenics Pharmaceuticals
$75,000,000
Follow-OnCo-Manager
August 2018
Acer Therapeutics
$46,000,000
Follow-OnCo-Manager
August 2018
ATEA Pharmaceuticals
$27,600,000
Series C Convertible Preferred StockPlacement Agent
July 2018
Aquestive Therapeutics
$74,000,000
IPOFinancial Advisor
July 2018
Cellectar Biosciences
$16,560,000
Follow-OnCo-Manager
July 2018
NightHawk Biosciences
$20,700,000
Follow-OnCo-Manager
May 2018
Rezolute
$5,000,000
PIPESole Placement Agent
April 2018
Scynexis
$30,000,000
Follow-OnCo-Manager
March 2018
AIT Therapeutics
$9,820,000
PIPECo-Placement Agent
February 2018
Applied Therapeutics
$6,000,000
Convertible NoteSole Placement Agent
February 2018
Union Acquisition Corp.
$115,000,000
IPOLead Manager
February 2018
Q BioMed
$5,500,000
Follow-OnCo-Lead Placement Agent
January 2018
Tolerion
$23,000,000
Series B Convertible Preferred StockSole Placement Agent
December 2017
Neumentum
$6,000,000
Series A Convertible Preferred StockSole Placement Agent
November 2017
Invesco High Income Closed End Fund 2024
$140,000,000
IPOCo-Manager
November 2017
BNY Mellon Global Credit Income 2024 Target Term Fund
$216,000,000
IPOCo-Manager
October 2017